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Introduction
Pertussis has been an important cause of morbidity and
mortality for centuries [1] and remains a significant cause of
infant mortality worldwide [2]. During the 1940s and 1950s, many
industrialized countries implemented widespread pertussis immu-
nization programmes, which resulted in dramatic declines in
disease incidence. In the last decade, however, a growing number
of highly vaccinated countries, such as the US [3], Canada [4],
France [5] and the Netherlands [6], have reported an increasing
trend in the general incidence of pertussis. This potential
resurgence has raised serious concerns about the effectiveness of
current pertussis vaccination strategies [7–9] and whether pertussis
eradication is an achievable goal [10]. Our understanding of
pertussis epidemiology has been complicated by the accumulation
of evidence that in some individuals the immunity acquired from
natural infection is not permanent [11–13], as was traditionally
postulated [14,15]. The upsurge in reported incidence has led to
the hypotheses that loss of immunity to pertussis is more
widespread than previously thought, that vaccine-induced immu-
nity may wane more rapidly than that acquired from natural
infection, and that vaccination may have a greater impact on the
severity of disease rather than on the transmission of infection.
Accurate assessment of the duration of immunity after natural
infection or vaccination is crucial for pertussis control, and yet our
understanding of immunity to pertussis is limited. The central
obstacle is that despite a great deal of clinical research, it remains
impossible to correlate protection against pertussis with a
quantifiable immune response against a single protective antigen
[16–18]. This is partly because, in contrast to other vaccine-
preventable bacterial infections, such as diphtheria or tetanus,
where antibodies are known to protect against the toxin that
mediates disease, pertussis produces a range of toxins including
pertussis toxin, endotoxin, adenylate cyclase toxin and tracheal
cytotoxin, which are known to play a role in pathogenesis and
immune evasion [19]. Immunity to pertussis is further complicated
by the production of numerous virulence factors (filamentous
hemagglutinin, pertactin and fimbriae) that aid bacterial persis-
tence in the respiratory tract. Moreover, in addition to binding to
epithelial cells in the respiratory tract (which facilitates extracel-
lular multiplication), pertussis also survives within macrophages
and other cell types, an observation that argues for a role for cell-
mediated as well as humoral immunity in protection [19,20].
A recent review by Wendelboe et al. [21] of the handful of
published studies on duration of immunity suggested estimates in
the range 7–20 years for naturally acquired immunity and 4–12
years for vaccine-induced immunity against disease. The wide
range in estimates may be due to a combination of differences in
study methodology and pertussis epidemiology in different
countries. Recent estimates of naturally acquired immunity are
generally based on a very small set of studies conducted in the
vaccine era. Estimates of vaccine-induced immunity are often
difficult to make because vaccine efficacy (primary vaccine failure)
and waning immunity (secondary vaccine failure) are confounded,
and potentially affected by variation in vaccine content, manu-
facture and schedule.
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clinical approaches, and the limitations of using cohort and case
series studies, a number of researchers have studied pertussis
transmission models to explore how waning immunity influences
pertussis epidemiology in the vaccine era [22,23], paying
particular attention to its consequences for the age-specific
serological profile [24] and the severity of disease [25]. However,
a systematic assessment of the degree of waning immunity that is
consistent with temporal and spatial incidence data, both in the
pre-vaccine and vaccine era, is lacking. As a first step toward
achieving this, we need testable predictions about the various
dynamical signatures we may expect to observe in epidemiological
data, such as the temporal patterns of outbreak dynamics, spatial
synchrony and fade-out structure. Here, we outline a simple model
for pertussis immunity and transmission and compare predictions
with epidemiological data for two key dynamical metrics–inter-
epidemic period and critical community size, defined as the
minimum population size above which pertussis remains endemic.
Methods
A model for pertussis immunity and transmission
To study the importance of waning immunity in shaping the
epidemiology of pertussis, we adopt an extension of the classic
Susceptible-Exposed-Infectious-Recovered (SEIR) paradigm that
accounts for reinfection and the possibility of both primary and
repeat infections. In Figure 1 we illustrate how the compartmental
model is set up, along with the system of deterministic differential
equations that formally describe the dynamics. We divide the
susceptible population into those who are naive to exposure (S1)
and those who have previously been infected or vaccinated (S2).
Similarly, exposed and infected individuals are divided into those
who are experiencing primary (E1, I1) and repeat infections (E2, I2)
[24], while the variable, R, represents all those who are recovered
and temporarily protected from natural infection. To incorporate
vaccination, we assume that a proportion, p, of newborns is
successfully immunized and enters the vaccinated class (V). The
parameter p, therefore, is a composite measure taking into account
both vaccine uptake and primary vaccine failure. Immunized
individuals may lose their immunity and become susceptible (S2).
We examine two distinct scenarios relating to the fate of S2
individuals who become exposed. First, in our basic model, we
assume they may experience repeat infections in a manner similar
to those who acquire immunity from natural infection. Or, second,
in our immune-boosting model, we assume that with probability e,
exposure may boost their immunity whereupon they revert to the
temporary immune class, R.
Distinguishingbetweenprimaryandrepeatinfectionswillallowus
to consider how variations in disease severity (e.g. if repeat infections
are less symptomatic than primary infections) could potentially affect
reported case numbers. The distinction between infection and
disease plays a fundamental role in the hypothesis that natural or
vaccine-induced immunity is not permanent. Most severe cases of
typical pertussis still occur in the very young (infants who are not yet
immunized), which suggests that if repeat bouts of infection occur,
they result in reduced disease [25]. Because most reported cases are
those exhibiting clinically presenting symptoms, a key issue is how
important unknowninfectionsare forpertussis transmission and thus
persistence. There are potentially two unseen cohorts: those with
atypical symptoms such as a persistent cough, who are probably
contributing to transmission; and those with asymptomatic infec-
tions, who are less likely to be contributing to transmission but are
boosting their own immunity and important to herd immunity. In
the model, loss of immunity is incorporated in a very simple manner:
weassumethat immunity,although temporary,iscomplete,and that
it is lost at a constant rate represented by an for naturally acquired
immunity and av for vaccine-induced immunity.
To explore the consequences of different assumptions about
waning immunity and the role of repeat infections, we develop a
stochastic event-driven analogue of the model presented in Figure 1
(see, for example, [26]). Specifically, we transform our determin-
istic model into its stochastic analogue using an approximation to
Gillespie’s direct algorithm [27] known as the t-leap method
[28,29]. We use a time-step of 0.001 year (&0:365 day), which was
found to yield significant speed-up without sacrificing accuracy
when compared to Gillespie’s direct algorithm for some initial test
cases. We simulate the model for various population sizes as key
immunity and transmission parameters are systematically varied.
This allows us to investigate the realized inter-epidemic period and
critical community size in both the pre-vaccine and vaccine eras.
Parameter values
An important initial step in generating model predictions is
determining parameter values. Certain epidemiological and
demographic characteristics, such as the average length of the
latent and infectious periods [30] and the average life expectancy
(death rate
21) are relatively well defined by independent data
(these parameter values are fixed throughout our investigations
and their values are listed in Table 1). In addition, we calculate
estimates of the range of birth rates over the period from
demographic data on the England and Wales cities. For simulation
purposes, we randomly choose a rate from the range in the pre-
vaccine era (and then decrease this in the vaccine era) for each
realization. With a fixed death rate, this leads to a non-stationary
population size that may affect the force of infection through
frequency-dependent transmission. To understand how this might
change model predictions, we conducted simulations in two
different ways: one where we recalculated the population size to
use in the force of infection, and another where we kept it fixed at
the initial size. For the range of birth rates used, and the length of
time series analyzed, both methods yielded very similar results.
By contrast, direct estimation of transmission rates is substantially
more problematic. In the past, employing results derived from
mathematical models, estimates of the average age at (first) infection
(Ap) have been used to infer transmission rates [31]. For pertussis,
this has resulted in the widely-used estimate of the basic
reproductive ratio, R0&L=Ap~17 in the pre-vaccine era in
England and Wales (based on Ap&4 and average life expectancy,
L~1=m, of 70 years). This estimate relies on the assumption of
permanent immunity, and so for our model we recalculate
transmission rates and R0 for different assumptions about waning
Author Summary
The eradication of vaccine-preventable infectious diseases
remains an important public health priority. To achieve this
goal, the level of immunity afforded needs to be high and
long-lasting. For pertussis, one of the leading causes of
mortality in infants, immunity has been shown to wane in
some individuals. The epidemiological impacts of this
observation depend critically on the duration of protective
immunity in the entire population, which remains notori-
ously difficult to estimate. We approach this problem by
exploring the agreement between model dynamics and
case notification data from England & Wales. Our estimates
suggest the average duration of immunity is much longer
than is currently thought (at least 30 years), but that some
individuals would lose immunity quite rapidly.
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details). In general, if we fix the average age at infection, waning
immunity results in a reduction in the estimated value of R0,v i aa
reduction in transmission rates. This is entirely intuitive: an
infectious disease which does not confer long-lasting immunity
does not need to be as transmissible to attain the same prevalence as
one that results inpermanent immunity, because lower transmission
is offset by faster replenishment of the susceptible pool.
Apotentialpitfallofsuchananalysiswould betoallowparameters
to vary independently because changes in assumed immunity
characteristics affect the basic reproductive ratio, R0 (see Appendix
S1 for details; [29]). Therefore, in order to ensure our model
dynamics conform to important epidemiological observations [31],
we constrain our transmission traits as immunity parameters are
varied to keep the mean age at primary infection fixed at 4 years.
To compare our model predictions to data, we record new cases
(new arrivals to the recovered class) and assume that 15% of
primary infections are reported and only 1% of repeat infections
(below, we discuss the effects of varying the reporting rate). Our
primary reporting rate was calibrated (in the pre-vaccine era and
in the absence of reporting repeat infections) so that the number of
case reports predicted by the model quantitatively agrees with
observed values in the England and Wales data and is supported
by the work of Clarkson & Fine [32]. This calibration holds as we
vary certain transmission and immunity parameters, because by
fixing the age at primary infection, the equilibrium level of
primary infections does not depend on the number of repeat
infections (see Appendix S1).
Results
Inter-epidemic periods
We begin by comparing model predictions about the inter-
epidemic periods to observations from England and Wales in the
Figure 1. A model of pertussis immunity and transmission: an extension of the SEIR paradigm that allows for reinfection and
gamma-distributed infectious periods. The parameter n denotes the background birth rate, m the background death rate, bij is the transmission
rate from infected individuals Ij to susceptible individuals Si, and 1=ci is the average length of infectiousness, where i, j=1 represents primary
infections and i, j=2 represents repeat infections. To mimic the opening and closing of schools, which affects transmission between children [40], we
assume that b11(t)~b1(1za) during term time and b11(t)~b1(1{a) during school holidays [41]. In addition, because we would like to focus on the
relative infectiousness of repeat infections to primary infections (g), and the relative magnitude of the contact rates, we rewrite the transmission rates
as b12~gxb0, b21~xb0 and b22~gjb0, where b0 is the average transmission rate from individuals with a primary infection to naive individuals.
Following the work of Nguyen & Rohani [42], we assume that the infectious period is gamma-distributed with shape parameter n=4. The parameter e
represents the probability that susceptible (but previously infected or vaccinated) individuals, upon exposure, boost their immunity instead of
becoming infectious. In the basic model, e~0 and in the immune-boosting model, 0veƒ1.
doi:10.1371/journal.ppat.1000647.g001
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1972, inclusive) when inter-epidemic periods were in the range 2–
3 years and 3–4 years respectively [26,33,34]. Figure 2 summa-
rizes the dominant periods of fifty stochastic realizations of the
basic model for 20 different population sizes (from 75,000 to 1.5
million, a range which represents all sizes of city in the data) as we
vary the duration of immunity in the pre-vaccine and vaccine era.
Model results (black markers) are displayed below the same
analyses performed on the data (gray markers). The diameter of a
marker centered at a particular value of cycle period reflects the
proportion of time series for which that period was the dominant
signal. For example, in Figure 2A, if we consider the horizontal
line of markers corresponding to an average duration of immunity
of 10 years, we can see that most of the realizations result in time
series with a detectable dominant period of around 2.5 years. For
each set of realizations, represented by a different duration of
immunity, we compare the set of dominant periods to those found
in the data. The percentage overlap between the two sets is then
displayed to the right in each panel.
The observed and predicted periods exhibit variation due to
variability in birth rates, population sizes and stochastic effects. In
the pre-vaccine era, variation in the predicted inter-epidemic period
and the influence of annual term-time forcing decreases as the
duration of immunity is reduced. The parameter values that most
closely correspond to the data (63–69% overlap) are those which
result in an average duration of immunity of at least 60 years (the
best-fit is permanent immunity). With the introduction of
vaccination, the inter-epidemic period increases, but this is only
significant when natural immunity is relatively long-lived. In the
vaccine era, under the assumption that vaccine-induced immunity
lasts as long as natural immunity (Figure 2B), the parameter values
that most closely correspond to the data (76–88% overlap) are those
which result in an average duration of natural immunity of between
50 and 80 years (the best-fit is 60 years). If we take the extreme
position that vaccine-induced immunity is very short-lived, with an
average duration of 10 years (Figure 2C), then the overlap with the
data is the same or worse for all but permanent immunity. When we
consider the overlap between data and model output as we
systematically vary both natural and vaccine-induced immunity, we
find that for natural immunity greater than 40 years (excluding
permanent immunity), there is some optimum duration of vaccine-
induced immunity that gives rise to a high percentage overlap with
the data (see Figure S2). In general, the average of the two durations
appears to be between 50 and 60 years. Aggregating the results on
inter-epidemic periods from both eras, we find that average
durations of natural immunity of 60–100 years are consistent with
the data. In addition, vaccine-induced immunity is likely to be
shorter, in some cases much shorter, than natural immunity.
In Figure 3, we present parallel results of the periodicity analysis
for our immune-boosting model. Epidemic dynamics are most
parsimonious with pre-vaccination England and Wales data when
1=an is at least 50 years(Figure3A). In the vaccine era, if the average
duration of vaccine-induced immunity is the same as that derived
from natural infection, the parameter values that most closely
correspond to the data (73–86% overlap) result in an average
duration of natural immunity of between 20 and 40 years, as shown
in Figure 3B. This range shifts to between 30 and 60 years if the
average duration of vaccine-induced immunity is fixed at 10 years
(Figure 3C). In general, including immune-boosting is dynamically
similar to increasing the average duration of immunity because
individuals experiencing immune-boosting are not infectious and
contributingtotransmission.However,becausetheeffectofboosting
is dependent on the repeat force of infection (l2), its impact varies
with the duration of natural immunity and the level of vaccination.
Table 1. Description and baseline values of parameters for the model. These are the values used unless otherwise stated.
Parameter Epidemiological description Value
Ap (pre-vaccine era) Average age at first infection 4 years
n (pre-vaccine era) Birth rate (0.012,0.028) year
21
n (vaccine era) Birth rate pre-vaccine rate - 0.002
m Death rate 1/70 year
21
1=s Average latent period 8 days
1=c1 Average infectious period for primary infections 15 days
1=c2 Average infectious period for repeat infections 15 days
b0 Average transmission rate from I1 to S1 see Appendix S1
a Relative amplitude of seasonal forcing 0.15
b1 Parameter in forcing function constrained b0
1za181=365
so that the average transmission rate is b0
g Relative infectiousness of repeat 1
to primary infections
x Ratio of contact rate between children and 0.5
adults to that between children
j Ratio of contact rate between adults 0.75
to that between children
e Immune-boosting probability 0 or 0.5
p (pre-vaccine era) Proportion of newborns successfully vaccinated 0
p (vaccine era) Proportion of newborns successfully vaccinated 0.6
doi:10.1371/journal.ppat.1000647.t001
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Next we explore whether critical community size (CCS) can
provide us with a further signature of waning immunity which may
be detected in the data. For both data and model output, we plot a
measure oftheextinctionfrequencyofthe disease (fade-outs) against
population size. We considered two different definitions and both
produced similar results: the one we present here is the proportion
of weeks with zero cases; the other measure we considered is the
number of times at least 3 consecutive weeks have zero cases per
epidemic. In the pre-vaccine era, analyses of fade-outs in the
stochastic basic model demonstrate that the CCS increases
gradually as the duration of naturally acquired immunity increases
(Figure 4A). Analyses of the England and Wales data suggest a CCS
of between 150,000 and 250,000 (blue markers, Figure 4C). The
extremes of very rapid loss of immunity or permanent immunity
result in CCSs slightly below or above this range, respectively.
When vaccination is implemented, the CCS increases for all
durations of immunity, except that the increase is more dramatic as
the duration of immunity increases (Figure 4B). In the vaccine era,
data from England and Wales suggest a CCS of between 800,000
and 1 million (red markers, Figure 4C), which is consistent with a
substantial period of immunity but not permanent immunity.
Given the immunity parameters that we used in our investigations,
we also determine which parameter generates a distribution of fade-
outs that most closely resembles the data. We quantify this by fitting
an exponential curve to the data in the two eras and then asking how
well this curve fits the fade-outs predicted by the stochastic model, as
assessed by the square of the residuals (see Figure 4D). We find the
results to be inconclusive in the pre-vaccine era (blue lines) because
there is not enough of a distinction between the fade-out profiles. In
the vaccine-era (assuming av~an), the results are quite different: the
average duration of immunity that leads to the smallest error is 80 or
100 years. This error is significantly smaller than that for all durations
of 40 years and below. Similar conclusions are reached if we fix av at
the best-fit value from the periodicity data. This result is also robust to
variations in the reporting rate of repeat infections. In fact, the lowest
errorsareobtainedbydiscountingallcasereportsofrepeatinfections.
The results of our analyses of the model with immune boosting
(Figure 5) are qualitatively very similar to those for the basic model
(Figure 4). The most notable difference is observed in the vaccine
era, where we obtain the closest agreement with the England &
Wales data (resulting in the lowest squared residuals) for a much
wider range of durations of immunity: between 40 and 100 years.
Robustness to changes in transmission parameters
For the basic model, together with the specific transmission
parameters investigated above, it appears that natural immunity of
an average duration of between 60 and 100 years gives the most
parsimonious fit with the data as measured by inter-epidemic
period and fade-out profile. We are also interested in understand-
Figure 2. Basic model: analyses of the dominant periods of the England and Wales pertussis data (gray markers) compared to the
dominant periods of stochastic realizations of the pertussis reinfection model (black markers), as the duration of immunity is
varied. Panel A illustrates results for the pre-vaccine era, panel B for the vaccine era assuming that av~an, and panel C for the vaccine era fixing the
average duration of vaccine-induced immunity at 10 years (av~0:1). The diameter of the marker reflects the proportion of the 50 largest cities (data)
or 1000 simulations (model: 50 realizations are generated for 20 different population sizes) for which spectral analysis of weekly case reports reveals
that period to be the dominant signal (note: as we show in Figure S11, increasing the number of stochastic realizations does not qualitatively affect
our findings). Any dominant period not significant at the 95% level is denoted as having a period of 0 years. The average normalized power for each
dominant signal is illustrated in Figure S1. The length of time series analyzed is 13 years in the pre-vaccine era, and 15 years in the vaccine era. The
percentages displayed to the right of each panel are the overlap between the data and the model output. Parameter values for the model are given
in Table 1, with e~0. The population size, N, is varied from 75,000 to 1.5 million. To allow for the reintroduction of infection following extinction in a
single population, we include a background force of infection of 50/million/yr (results are similar if we assume 10/million/yr). The axis representing
the average duration of immunity is not to scale between 100 years (an~0:01) and permanent immunity (an~0).
doi:10.1371/journal.ppat.1000647.g002
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parameters that are difficult to estimate empirically. The
parameter x represents the ratio of the contact rate between
children and adults to the average contact rate between children.
Decreasing the parameter to x~0:1 results in the same estimate of
60–100 years for the duration of natural immunity (Figures S3 and
S4). The parameter g represents the relative infectiousness of
repeat infections to primary infections; decreasing g reduces the
influence of repeat infections on the transmission process by
reducing their contribution to the force of infection, which is
dynamically very similar to increasing the immune-boosting
parameter e.I fg is close to zero, then primary infections are
responsible for almost all transmission so the duration of immunity
only plays a role in the prevalence of repeat infections. Because
asymptomatic infections are almost certain to go undetected, it is
unlikely that data can distinguish between different durations of
immunity in this case. However, if repeat infections are such that
g~0:5, the same analyses carried out for g~1 give similar results
(Figures S5 and S6), with the most parsimonious range of duration
of natural immunity shifting to 30–80 years. As is the case for the
immune-boosting model when e~0:5.
Discussion
Obtaining an accurate assessment of the duration of pertussis
immunity is essential for informing pertussis vaccination policy [35].
In this paper, we have attempted to explore this question by
interrogating transmission models to ascertain the duration of
immunity that is most parsimonious with historical case notification
data from England & Wales. We find that, irrespective of model
choice, assuming a very short duration of natural immunity (on
average less than 30 years) or permanent immunity generates
predictions inconsistent with the pre-vaccine and vaccine era data
from England and Wales. Shorter durations of immunity to pertussis
lead to no increase in the inter-epidemic period and only a small
increase in the CCS. Permanent immunity to pertussis results in a
dramatic increase in inter-epidemic period and CCS. Our analyses
found that a range of durations of naturally acquired immunity is
consistent with the pre-vaccine and vaccine era data. If repeat
infections are as infectious as primary infections with no immune-
boosting then this range is 60–100 years, if they are half as infectious
or 50% lead to immune-boosting infections, then this range is 30–80
years. These values are robust to changes in primary-repeat contact
rates and variation in the reporting rate of repeat infections.
Our estimates of the average duration of natural immunity are
somewhat higher than those reported in the epidemiological
literature [21]. This may be in part because it is difficult to conduct
a study to detect and fully sample the entire distribution of waning
immunity periods amongst individuals in a population. Second, we
have made a key assumption about waning immunity in our model
that our predictions may rely on. The assumption, which is
inherent to the standard SEIRS models, is that duration of
Figure 3. Immune-boosting model: analyses of the dominant periods of the England and Wales pertussis data (gray markers)
compared to the dominant periods of stochastic realizations of the pertussis reinfection model with immune boosting (black
markers), as the duration of immunity is varied. Panel A illustrates results for the pre-vaccine era, panel B for the vaccine era assuming that
av~an, and panel C for the vaccine era fixing the average duration of vaccine-induced immunity at 10 years (av~0:1). The diameter of the marker
reflects the proportion of the 50 largest cities (data) or 1000 simulations (model: 50 realizations are generated for 20 different population sizes) for
which spectral analysis of weekly case reports reveals that period to be the dominant signal. Any dominant period not significant at the 95% level is
denoted as having a period of 0 years. The length of time series analyzed is 13 years in the pre-vaccine era, and 15 years in the vaccine era. The
percentages displayed to the right of each panel are the overlap between the data and the model output. Parameter values for the model are given
in Table 1, with e~0:5. The population size, N, is varied from 75,000 to 1.5 million. To allow for the reintroduction of infection following extinction in a
single population, we include a background force of infection of 50/million/yr (results are similar if we assume 10/million/yr). The axis representing
the average duration of immunity is not to scale between 100 years (an~0:01) and permanent immunity (an~0).
doi:10.1371/journal.ppat.1000647.g003
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substantial variance around the mean (the coefficient of variation
is 1) and many individuals will lose immunity quickly and some
never at all. If we consider the time taken for 25% of the
population to lose immunity, estimates of the average duration of
immunity between 50 and 80 years would predict that this lies in
the range 14–23 years (see Figure 6). Moreover, more than 10% of
the population would have lost immunity within 10 years, which is
not in contradiction with clinical reports.
We extended both models to consider a gamma-distributed
immune period (with two classes, leading to a coefficient of
variation of 0.7). This model was less parsimonious with the data,
especially in the pre-vaccine era when it predicted longer inter-
epidemic periods and higher CCSs (Figures S7, S8, S9 and S10).
What these results suggest is that pertussis immunity is inherently
variable, and efforts to understand waning immunity of pertussis
require knowledge of the distribution of immune periods.
Unfortunately, our analyses are less conclusive about the
average duration of vaccine-derived immunity. However, for the
range of natural immunity consistent with the pre-vaccine era
data, the corresponding durations of vaccine-derived immunity
that give the best agreement with the data in the vaccine era are
generally shorter than the duration of natural immunity (and are
very short for the longest durations of natural immunity). Parsing
out the effects of different durations of vaccine-derived immunity
will require longer time series and potentially better data on
‘‘silent’’ repeat infections. This could be approached by consid-
ering longer datasets from the vaccine era. However, later
perturbations in vaccine uptake (during the mid-1970s) and
changes in vaccine content and protocols add further complexity
to determining the duration of vaccine-induced immunity.
Our model analyses highlight a number of robust findings.
Assuming that asymptomatic infections are unobserved, we find
model output to be in strong agreement with empirical patterns as
Figure 4. Basic model: the effects of waning immunity on critical community size. Panels A and B illustrate analyses of weekly fade-outs in
the stochastic model in the pre-vaccine and vaccine era as the average duration of immunity (1=an) is varied. Panel C shows fade-out analyses for the
England and Wales data in the pre-vaccine (blue) and vaccine (red) eras: open circles denote data points and solid lines the best-fit exponential curve.
Panel D demonstrates the results of fitting model output to the fade-out curves shown in C, as assessed by the square of the residuals: the blue lines
represent the pre-vaccine era; the red lines represent the vaccine era assuming that vaccine-induced immunity is lost at the rate av~an. Solid lines
denote averages and dashed lines indicate the 90% confidence envelope. For the stochastic model, weekly fade-outs are calculated as the average
number of weeks per year with zero case reports, assuming a 15% primary reporting rate and 1% secondary reporting rate, averaged over 50
realizations for each population size. Parameter values for the model are given in Table 1, with e~0. In panels A, B and D, the axis representing the
average duration of immunity is not to scale between 100 years (an~0:01) and permanent immunity (an~0).
doi:10.1371/journal.ppat.1000647.g004
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decrease the infectiousness of repeat infections (g) or (iii) increase
the probability that, upon exposure, there is immune boosting of
those whose immunity had waned (e). In turn, the implications of
these observations are that (i) natural pertussis infection induces,
on average, considerably long-lasting immunity, (ii) repeat
infections contribute relatively little to the transmission cycle,
and (iii) secondary exposures generate few infections (and may lead
mostly to immune boosting). Taken together, these conclusions
raise doubts over the impact of repeat infections in pertussis
dynamics. If correct, these findings represent reasonably encour-
aging news for pertussis control, indicating that a reduction in
prevalence (and an increase in the CCS) is possible with continued
focus on increasing vaccine uptake and reducing both primary and
secondary vaccine failure.
Although our study was not designed to address the issue of the
recent resurgence in pertussis in certain countries, our model
analyses, based on the England and Wales data, suggest that loss of
natural immunity is not the primary driver. Perhaps what we
should be focusing on are perturbations to pertussis dynamics in
the modern era. These may include demographic changes,
pathogen evolution, and perturbations in vaccine manufacture,
uptake and efficiency, all of which are likely to have significant
dynamical impacts. In particular, the vaccine era data considered
in this study span 1958–1972 when the whole cell vaccine was in
use. Extrapolation of our analyses to modern data with a variety of
acellular vaccines and a booster schedule would be difficult,
especially in light of known differences in the Th1/Th2 response
of the whole cell and acellular vaccines [19].
Finally, this work suggests a revision of estimates of the basic
reproductive ratio, or R0, of pertussis. As mentioned above, the
classic work of Anderson & May [31] has been pivotal in
suggesting that the R0 of pertussis is in the range of 14–17, with the
attendant control implications that vaccine coverage must be very
Figure 5. Immune-boosting model: the effects of waning immunity on critical community size. Panels A and B illustrate analyses of
weekly fade-outs in the stochastic model in the pre-vaccine and vaccine era as the average duration of immunity (1=an) is varied. Panel C shows fade-
out analyses for the England and Wales data in the pre-vaccine (blue) and vaccine (red) eras: open circles denote data points and solid lines the best-
fit exponential curve. Panel D demonstrates the results of fitting model output to the fade-out curves shown in C, as assessed by the square of the
residuals: the blue lines represent the pre-vaccine era; the red lines represent the vaccine era assuming that vaccine-induced immunity is lost at the
rate av~an. Solid lines denote averages and dashed lines indicate the 90% confidence envelope. For the stochastic model, weekly fade-outs are
calculated as the average number of weeks per year with zero case reports, assuming a 15% primary reporting rate and 1% secondary reporting rate,
averaged over 50 realizations for each population size. Parameter values for the model are given in Table 1, with e~0:5. In panels A, B and D, the axis
representing the average duration of immunity is not to scale between 100 years (an~0:01) and permanent immunity (an~0).
doi:10.1371/journal.ppat.1000647.g005
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Their estimates were based on the well-known relationship
between the mean age at (primary) infection and life expectancy,
derived from models assuming permanent immunity [29,31]. The
estimates of R0 in systems where immunity is not permanent are
substantially impacted by the duration of immunity [29].
Following our analyses, we find that, in the pre-vaccine era, the
corresponding values of R0 fall in the range 11–15 (Figure 7).
These values are lower than those commonly cited in the
epidemiological literature, and paint a somewhat rosier picture
regarding pertussis control. This conclusion, however, needs to be
tempered by the recognition that control of infectious diseases is
made much harder when using imperfect vaccines [36–38],
especially in the face of waning immunity [39].
Supporting Information
Figure S1 Reproduction of Figure 2 in the main text, with
marker color representing the average normalized power corre-
sponding to each dominant period. Panel A illustrates results for
the pre-vaccine era, panel B for the vaccine era assuming that
av=an, and panel C for the vaccine era fixing the average duration
of vaccine-induced immunity at 10 years (av=0.1).
Found at: doi:10.1371/journal.ppat.1000647.s001 (0.36 MB TIF)
Figure S2 Basic model: the percentage overlap between the
dominant periods detected in the data and those detected in the
model output as both the duration of natural immunity (1/an) and
vaccine-induced immunity (1/av) are varied in the vaccine era.
Values of 1/av above 50 years give very similar results to 1/av=50
(because we are only considering 15 years of time series in the
vaccine era.)
Found at: doi:10.1371/journal.ppat.1000647.s002 (0.12 MB TIF)
Figure S3 Basic model: the effects of waning immunity on inter-
epidemic period when the relative contact rate between children
and adults is very low (x=0.1). Panel A illustrates results for the
pre-vaccine era, panel B for the vaccine era assuming that av=an,
and panel C for the vaccine era fixing the average duration of
vaccine-induced immunity at 10 years (av=0.1). Compare to
Figure 2 in the main text.
Found at: doi:10.1371/journal.ppat.1000647.s003 (0.29 MB TIF)
Figure S4 Basic model: the effects of waning immunity on
critical community size when the relative contact rate between
children and adults is very low (x=0.1). Panels A and B illustrate
analyses of weekly fade-outs in the stochastic model in the pre-
vaccine and vaccine era as the average duration of immunity (1/
an) is varied. Panel C shows fade-out analyses for the England and
Wales data in the pre-vaccine (blue) and vaccine (red) eras: open
circles denote data points and solid lines the best-fit exponential
curve. Panel D demonstrates the results of fitting model output to
the fade-out curves shown in C, as assessed by the square of the
residuals: the blue lines represent the pre-vaccine era; the red lines
represent the vaccine era assuming that vaccine-induced immunity
is lost at the rate av=an. Solid lines denote averages and dashed
lines indicate the 90% confidence envelope. Compare to Figure 4
in the main text.
Found at: doi:10.1371/journal.ppat.1000647.s004 (0.58 MB TIF)
Figure S5 Basic model: the effects of waning immunity on inter-
epidemic period when repeat infections are half as infectious as
primary infections (g=0.5). Panel A illustrates results for the pre-
vaccine era, panel B for the vaccine era assuming that av=an, and
panel C for the vaccine era fixing the average duration of vaccine-
induced immunity at 10 years (av=0.1). Compare to Figure 2 in
the main text.
Found at: doi:10.1371/journal.ppat.1000647.s005 (0.29 MB TIF)
Figure S6 Basic model: the effects of waning immunity on
critical community size when repeat infections are half as
infectious as primary infections (g=0.5). Panels A and B illustrate
analyses of weekly fade-outs in the stochastic model in the pre-
vaccine and vaccine era as the average duration of immunity (1/
an) is varied. Panel C shows fade-out analyses for the England and
Figure 6. The proportion of individuals who have lost
immunity as a function of time since infection, under different
assumptions about the average duration of naturally acquired
immunity (1= = =an) and the distribution of the immune period. The
gamma-distributed periods are both with shape parameter k=2,
equivalent to assuming two sub-classes.
doi:10.1371/journal.ppat.1000647.g006
Figure 7. The value of R0 as the degree of immune-boosting (e)
and the rate of waning immunity (an) are varied for a fixed
value of the mean age at primary infection. All other parameters
are defined in Table 1. The mathematical formula for R0 is given in
Appendix S1.
doi:10.1371/journal.ppat.1000647.g007
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circles denote data points and solid lines the best-fit exponential
curve. Panel D demonstrates the results of fitting model output to
the fade-out curves shown in C, as assessed by the square of the
residuals: the blue lines represent the pre-vaccine era; the red lines
represent the vaccine era assuming that vaccine-induced immunity
is lost at the rate av=an. Solid lines denote averages and dashed
lines indicate the 90% confidence envelope. Compare to Figure 4
in the main text.
Found at: doi:10.1371/journal.ppat.1000647.s006 (0.61 MB TIF)
Figure S7 Basic model: the effects of waning immunity on inter-
epidemic period when the immune class R is gamma-distributed
with k=2. Panel A illustrates results for the pre-vaccine era, panel
B for the vaccine era assuming that av=an, and panel C for the
vaccine era fixing the average duration of vaccine-induced
immunity at 10 years (av=0.1). Compare to Figure 2 in the main
text.
Found at: doi:10.1371/journal.ppat.1000647.s007 (0.29 MB TIF)
Figure S8 Basic model: the effects of waning immunity on
critical community size when the immune class R is gamma-
distributed with k=2. Panels A and B illustrate analyses of weekly
fade-outs in the stochastic model in the pre-vaccine and vaccine
era as the average duration of immunity (1/an) is varied. Panel C
shows fade-out analyses for the England and Wales data in the
pre-vaccine (blue) and vaccine (red) eras: open circles denote data
points and solid lines the best-fit exponential curve. Panel D
demonstrates the results of fitting model output to the fade-out
curves shown in C, as assessed by the square of the residuals: the
blue lines represent the pre-vaccine era; the red lines represent the
vaccine era assuming that vaccine-induced immunity is lost at the
rate av=an. Solid lines denote averages and dashed lines indicate
the 90% confidence envelope. Compare to Figure 4 in the main
text.
Found at: doi:10.1371/journal.ppat.1000647.s008 (0.69 MB TIF)
Figure S9 Immune-boosting model: the effects of waning
immunity on inter-epidemic period when the immune class R is
gamma-distributed with k=2. Panel A illustrates results for the
pre-vaccine era, panel B for the vaccine era assuming that av=an,
and panel C for the vaccine era fixing the average duration of
vaccine-induced immunity at 10 years (av=0.1). Compare to
Figure 3 in the main text.
Found at: doi:10.1371/journal.ppat.1000647.s009 (0.29 MB TIF)
Figure S10 Immune-boosting model: the effects of waning
immunity on critical community size when the immune class R is
gamma-distributed with k=2. Panels A and B illustrate analyses of
weekly fade-outs in the stochastic model in the pre-vaccine and
vaccine era as the average duration of immunity (1/an) is varied.
Panel C shows fade-out analyses for the England and Wales data
in the pre-vaccine (blue) and vaccine (red) eras: open circles denote
data points and solid lines the best-fit exponential curve. Panel D
demonstrates the results of fitting model output to the fade-out
curves shown in C, as assessed by the square of the residuals: the
blue lines represent the pre-vaccine era; the red lines represent the
vaccine era assuming that vaccine-induced immunity is lost at the
rate av=an. Solid lines denote averages and dashed lines indicate
the 90% confidence envelope. Compare to Figure 5 in the main
text.
Found at: doi:10.1371/journal.ppat.1000647.s010 (0.69 MB TIF)
Figure S11 Basic model: qualitatively similar findings when the
number of stochastic realizations is increased to 500 replicates per
population size. Panel A illustrates periodicity results for the pre-
vaccine era, panel B for the vaccine era assuming that av=an, and
panel C for the vaccine era fixing the average duration of vaccine-
induced immunity at 10 years (av=0.1). Panels D and E illustrate
analyses of weekly fade-outs in the stochastic model in the pre-
vaccine and vaccine era as the average duration of immunity (1/
an) is varied. Panel F shows fade-out analyses for the England and
Wales data in the pre-vaccine (blue) and vaccine (red) eras: open
circles denote data points and solid lines the best-fit exponential
curve. Panel G demonstrates the results of fitting model output to
the fade-out curves shown in F, as assessed by the square of the
residuals: the blue lines represent the pre-vaccine era; the red lines
represent the vaccine era assuming that vaccine-induced immunity
is lost at the rate av=an. Solid lines denote averages and dashed
lines indicate the 90% confidence envelope. Compare to Figures 2
and 4 in the main text.
Found at: doi:10.1371/journal.ppat.1000647.s011 (0.65 MB TIF)
Appendix S1
Found at: doi:10.1371/journal.ppat.1000647.s012 (0.03 MB PDF)
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